NasdaqGS:PTCTBiotechs
Can PTC Therapeutics' (PTCT) New PKU Partnership Reveal Its Long-Term Rare Disease Strategy?
RareMed Solutions recently announced an expanded partnership with PTC Therapeutics, launching non-commercial pharmacy dispensing services for Sephience™, following its FDA approval for phenylketonuria (PKU) in adult and pediatric patients.
This collaboration aims to provide comprehensive patient support and demonstrates how stakeholder partnerships can enhance access and coordination for innovative rare disease therapies.
We'll next explore how Sephience's approval and enhanced patient...